Patents by Inventor Angela Anigbogu

Angela Anigbogu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FORMULATIONS AND METHODS FOR PROVIDING PROGESTIN-ONLY CONTRACEPTION
    Publication number: 20220117977
    Abstract: Formulations and methods for providing progestin-only contraception to a woman including transdermally administering to a woman a formulation having a contraceptively effective amount of progestin-only hormonal agents as part of a contraceptive regimen.
    Type: Application
    Filed: December 29, 2021
    Publication date: April 21, 2022
    Applicant: ALLERGAN SALES, LLC
    Inventors: Charles Ebert, Gary Hoel, Angela Anigbogu, Samir Roy
  • FORMULATIONS AND METHODS FOR PROVIDING PROGESTIN-ONLY CONTRACEPTION WHILE MINIMIZING ADVERSE SIDE EFFECTS ASSOCIATED THEREWITH
    Publication number: 20200061082
    Abstract: Formulations and methods for providing progestin-only contraception to a woman including transdermally administering to a woman a formulation having a contraceptively effective amount of progestin-only hormonal agents as part of a contraceptive regimen.
    Type: Application
    Filed: November 1, 2019
    Publication date: February 27, 2020
    Applicant: ALLERGAN SALES, LLC
    Inventors: Charles Ebert, Gary Hoel, Angela Anigbogu, Samir Roy
  • Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith
    Patent number: 10500215
    Abstract: Formulations and methods for providing progestin-only contraception to a woman while minimizing various side effects, such as breakthrough bleeding, that are normally associated with progestin-only contraception are disclosed and described. In one aspect, the method can include transdermally administering a formulation having a contraceptively effective amount of a single progestin as the sole active hormonal agent to the woman as part of a contraceptive regimen.
    Type: Grant
    Filed: October 17, 2018
    Date of Patent: December 10, 2019
    Assignee: Allergan Sales, LLC
    Inventors: Charles Ebert, Gary Hoel, Angela Anigbogu, Samir Roy
  • FORMULATIONS AND METHODS FOR PROVIDING PROGESTIN-ONLY CONTRACEPTION WHILE MINIMIZING ADVERSE SIDE EFFECTS ASSOCIATED THEREWITH
    Publication number: 20190111063
    Abstract: Formulations and methods for providing progestin-only contraception to a woman while minimizing various side effects, such as breakthrough bleeding, that are normally associated with progestin-only contraception are disclosed and described. In one aspect, the method can include transdermally administering a formulation having a contraceptively effective amount of a single progestin as the sole active hormonal agent to the woman as part of a contraceptive regimen.
    Type: Application
    Filed: October 17, 2018
    Publication date: April 18, 2019
    Inventors: Charles Ebert, Gary Hoel, Angela Anigbogu, Samir Roy
  • Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith
    Patent number: 10137135
    Abstract: Formulations and methods for providing progestin-only contraception to a woman while minimizing various side effects, such as breakthrough bleeding, that are normally associated with progestin-only contraception are disclosed and described. In one aspect, the method can include transdermally administering a formulation having a contraceptively effective amount of a single progestin as the sole active hormonal agent to the woman as part of a contraceptive regimen.
    Type: Grant
    Filed: August 15, 2005
    Date of Patent: November 27, 2018
    Assignee: Allergan Sales, LLC
    Inventors: Charles Ebert, Gary Hoel, Angela Anigbogu, Samir Roy
  • Formulations and Methods for Enhancing the Transdermal Penetration of a Drug
    Publication number: 20070065494
    Abstract: Methods and formulations of enhancing the permeability the skin of a subject to a drug are disclosed. The method may include administering a combination of lauryl alcohol and isopropyl myristate as a penetration enhancer to the area of skin to provide synergistically enhanced penetration of the drug.
    Type: Application
    Filed: July 31, 2006
    Publication date: March 22, 2007
    Applicant: WATSON LABORATORIES, INC.
    Inventors: Angela Anigbogu, Samir Roy, Vesna Anteljevic
  • Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith
    Publication number: 20070037780
    Abstract: Formulations and methods for providing progestin-only contraception to a woman while minimizing various side effects, such as breakthrough bleeding, that are normally associated with progestin-only contraception are disclosed and described. In one aspect, the method can include transdermally administering a formulation having a contraceptively effective amount of a single progestin as the sole active hormonal agent to the woman as part of a contraceptive regimen.
    Type: Application
    Filed: August 15, 2005
    Publication date: February 15, 2007
    Inventors: Charles Ebert, Gary Hoel, Angela Anigbogu, Samir Roy
  • Norethindrone sustained release formulations and methods associated therewith
    Publication number: 20050058695
    Abstract: Sustained delivery formulations of norethindrone are disclosed and described. In one aspect, the formulation may be a transdermal formulation that includes both norethindrone and norethindrone acetate. In another aspect, the formulation may further include a penetration enhancer. Coadministration of norethindrone and norethindrone acetate has been found to provide a number of advantages, such as achievement of peak norethindrone serum levels substantially within 24 hours after initiation of administration.
    Type: Application
    Filed: December 17, 2003
    Publication date: March 17, 2005
    Inventors: Angela Anigbogu, Ana Ruiz, Danyi Quan
  • Norethindrone sustained release formulations and methods associated therewith
    Publication number: 20040037873
    Abstract: Sustained delivery formulations of norethindrone are disclosed and described. In one aspect, the formulation may be a transdermal formulation that includes both norethindrone and norethindrone acetate. In another aspect, the formulation may further include a penetration enhancer. Coadministration of norethindrone and norethindrone acetate has been found to provide a number of advantages, such as achievement of peak norethindrone serum levels substantially within 24 hours after initiation of administration.
    Type: Application
    Filed: May 30, 2003
    Publication date: February 26, 2004
    Applicant: WATSON PHARMACEUTICALS, INC.
    Inventors: Angela Anigbogu, Ana Ruiz, Danyi Quan